At the 42nd Annual Meeting of the European Society for Blood and Marrow Transplantation, held in Valencia, Spain, John Gribben, MD, from Barts Cancer Institute, London, UK, discusses how novel agents, like ibrutinib and idelalisib, lead to a reduction of allogeneic transplants in chronic lymphocytic leukemia (CLL). These new, effective treatments raise a question: Who are the patients and when allogeneic transplants should be offered?